Display Settings:

Format

Send to:

Choose Destination
Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 .

The safety of rosiglitazone in the treatment of type 2 diabetes.

Author information

  • 1Wake Forest University School of Medicine, Department of Medicine, Winston-Salem, NC 27103, USA. sosingh@wfubmc.edu

Abstract

BACKGROUND:

Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease.

OBJECTIVES:

To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone.

METHODS:

Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers.

CONCLUSION:

Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.

PMID:
18759710
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk